BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230208
DTEND;VALUE=DATE:20230210
DTSTAMP:20260516T051034
CREATED:20221025T104610Z
LAST-MODIFIED:20221025T104610Z
UID:35615-1675814400-1675987199@www.pharmajournalist.com
SUMMARY:14th Annual RNA Therapeutics Conference
DESCRIPTION:SAE Media Group invites you to join the 14th Annual RNA Therapeutics Conference\, taking place on 8 and 9 February 2023\, in London\, UK. \nBuilding on the success of previous years\, the RNA Therapeutics Conference will bring together industry experts from leading pharma and biotech companies to provide an expert and holistic view on the latest developments of the industry. \nRNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy\, personalised medicines\, and treatment of genetic\, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025\, growing at a CAGR of 7.5%. \nWith Covid-19 rapidly accelerating the RNA landscape through massive regulatory successes\, the recent advent of CRISPR\, an RNA-guided gene-editing technology\, as well as new strides in the delivery of messenger RNA transcribed in vitro\, there has been considerable progress in the development of RNA medicines and a major expansion of the RNA-therapeutics field. \nThis year’s conference will reflect on how the industry has adapted and played a pivotal role in global health over the past year and will discuss the takeaways for future mRNA therapeutic development. \nBenefits of attending: \n\nExplore how mRNA leads the way in the genetic medicine space as the next generation of novel drug modalities\nInvestigate the latest trends in AI drug discovery as a tool for designing novel RNA based therapeutics\nEnhance your knowledge of the latest innovations in RNA application and RNA delivery techniques with case studies from BioNTech\, Neuway Pharma and Ethris GmbH\nEngage in the growing advances and development of novel RNA molecules in the treatment of chronic respiratory\, neurodegenerative\, and infectious diseases\n\nWho should attend: \n\nDirectors of novel RNA therapies\nCEOs\nSenior and expert scientists\nChief Medical Officers\nChief Technical Officers\nSenior Vice Presidents\nGlobal Heads of mRNA R&D\nGlobal Medical Directors\nHeads of Translational Medicine\nDirector\, Clinical Pharmacology\nGlobal Head of RNA and Targeted Therapeutics\nClinical Science Director\nHead of Biology\nDirector\, Genetic Medicine\nAssociate Director\n\nEARLY-BIRD RATES: \n\nREGISTER BY 31ST OCTOBER AND SAVE £400\nREGISTER BY 3OTH NOVEMBER AND SAVE £200\nREGISTER BY 16TH DECEMBER AND SAVE £100
URL:https://www.pharmajournalist.com/event/14th-annual-rna-therapeutics-conference/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:lamprini.balasi@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230208
DTEND;VALUE=DATE:20230210
DTSTAMP:20260516T051034
CREATED:20221117T082926Z
LAST-MODIFIED:20221117T082926Z
UID:35834-1675814400-1675987199@www.pharmajournalist.com
SUMMARY:Healthcare Payment & Revenue Integrity Summit
DESCRIPTION:Introducing the only industry forum exclusively bringing together key decision-makers\, within health insurers and providers\, who are responsible for payment and revenue integrity\, value-based payment\, and networking relations. \nAt a time when both payers and providers are evaluating and streamlining internal payment and revenue integrity processes\, this networking conference has been established to breakdown silos\, by promoting discussion between clinical\, coding\, revenue cycle and payment departments to facilitate the development of efficient\, value-based healthcare systems. \nTo know more visit: https://healthcarepaymentrevenueintegritysummit.com
URL:https://www.pharmajournalist.com/event/healthcare-payment-revenue-integrity-summit/
LOCATION:ORLANDO\, FLORIDA
ORGANIZER;CN="Kisaco Research":MAILTO:marketing@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230208
DTEND;VALUE=DATE:20230210
DTSTAMP:20260516T051034
CREATED:20221128T102920Z
LAST-MODIFIED:20221128T103039Z
UID:35931-1675814400-1675987199@www.pharmajournalist.com
SUMMARY:6th Annual 3D Cell Culture Conference
DESCRIPTION:6th Annual 3D Cell Culture Conference \n8-9 February 2022 \nLondon\, UK\nhttp://www.3D-cellculture.com/PJwl \nSponsored: CelVivo\, Promega and Systemic Bio \nConference Co-chairs: \nPhillip Hewitt\, Global Head of Early Investigative Toxicology\, Merck \nRhiannon David\, Director\, Microphysiological Systems\, AstraZeneca  \nExploring the implementation of complex in-vitro models for drug development \nJoin us in February 2023\, as SAE Media Group’s 6th annual 3D Cell Culture Conference brings together industry experts from big pharma\, regulatory bodies\, and cutting-edge researchers to discuss the challenges and drivers of these medical technologies\, through case studies of the latest innovations in 3D Cell Culture models\, real world examples of clinical applications\, and insights into regulatory validation and high throughput screening to give a comprehensive look into this fast growing industry. \n3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years\, with the global 3D Cell Culture market predicted to reach a value of $3.48 Billion by 2028. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery\, pathology modelling and validation\, safety and toxicity. 3D Cell Culture technology promises to offer increased translatability in models and reduce the costly rates of drug attrition in the discovery process — heralding the next major advance in the discovery of pharmaceuticals. \nEvent Hashtag: #3DCellCulture2023 \nKey Conference Highlights: \n\nDiscuss the uses of advanced cell technologies for human tissue bioengineering\nUncover the major benefits of 3D modelling in enhancing clinical translation and predictability\nUtilise 3D cell culture for personalised drug screening and high-throughput screening over traditional 2D methods\nLearn how to implement 3D Cell Culture techniques for antibody and cell and gene therapy discovery process\nDelve into advanced case studies looking into organ models: from the blood-brain barrier to liver spheroids\n\nWho Should Attend? \nBiotech / Pharma Companies – Investigative toxicologist\, Research Scientist\, Clinical Pharmacologist\, Cell Technologists\, Cell and Molecular Scientist\, Head of Translational Research\,  In-Vitro Toxicologists\,  Director of Drug Discovery\, Head of DMPK\, Chief Scientific Officer\,  R&D Scientist\, Head of R&D. \nAcademia – Cell Technology\, Stem Cell Sciences\, Biochemistry\, Protein Technology and Tissue Engineering \nSolution Providers – Manager\, Head of\, CEO\, Director\, Founder\, Account Manager\, President\, CSO\, Executive\, Managing Director\, Vice President\, COO\, Biomedical Engineers\, Head of External Collaboration \nOrganisations / Regulatory – Director\, Senior Science Advisor\, Scientific Officer\, Advisor for Toxicology
URL:https://www.pharmajournalist.com/event/6th-annual-3d-cell-culture-conference/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:simi.sapal@saemediagroup.com
END:VEVENT
END:VCALENDAR